WO2005115324A1 - Dermatological composition for the treatment of pigmentary disorders of the skin - Google Patents

Dermatological composition for the treatment of pigmentary disorders of the skin Download PDF

Info

Publication number
WO2005115324A1
WO2005115324A1 PCT/FR2005/001213 FR2005001213W WO2005115324A1 WO 2005115324 A1 WO2005115324 A1 WO 2005115324A1 FR 2005001213 W FR2005001213 W FR 2005001213W WO 2005115324 A1 WO2005115324 A1 WO 2005115324A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
skin
fatty acid
mequinol
acid
Prior art date
Application number
PCT/FR2005/001213
Other languages
French (fr)
Inventor
Isabelle Pelisson
André Jomard
Cécile COUSIN
Original Assignee
Galderma Research & Development, S.N.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research & Development, S.N.C. filed Critical Galderma Research & Development, S.N.C.
Priority to JP2007512293A priority Critical patent/JP2007537218A/en
Priority to EP05770836A priority patent/EP1746971A1/en
Priority to CA002564100A priority patent/CA2564100A1/en
Publication of WO2005115324A1 publication Critical patent/WO2005115324A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Definitions

  • the invention relates to a skin depigmenting composition
  • a skin depigmenting composition comprising, in a physiologically acceptable medium, mequinol (or 4-hydroxyanisole), and at least one unsaturated or polyunsaturated fatty acid and its pharmaceutical or cosmetic use.
  • the composition according to the invention may also contain a sunscreen.
  • the pigmentation of the skin results from the synthesis of melanin in the melanocytes of the dermis by the transformation of tyrosine under the influence of a cuproprotein enzyme tyrosinase.
  • Mequinol is a compound whose depigmenting activity is known. Indeed it acts as a substrate for tyrosinase and therefore blocks the mechanism of melanin synthesis in the dermis (Riley P, Journal of Pathology (1969), 97 (2), 185-191) Indeed, disorders Pigments such as hyperpigmentation are the result of excessive production of melanin. By blocking or decreasing this synthesis, one can obtain a depigmentation effect
  • the invention relates to a depigmenting composition for the skin comprising, in a physiologically acceptable medium, mequinol and an unsaturated fatty acid.
  • physiologically acceptable medium means a medium compatible with the skin, the mucous membranes and / or the integuments.
  • fatty acid is meant a constituent of lipids.
  • the fatty acids differ from each other by their chain length and their degree of saturation, namely the number of carbon constituting the chain and the nature of the bonds, single or double, connecting the carbon atoms to each other.
  • saturated fatty acid according to the invention means the unsaturated fatty acids and the polyunsaturated fatty acids.
  • unsaturated fatty acid By way of nonlimiting example of unsaturated fatty acid according to the invention, mention may be made of linoleic acid, arachidonic acid, sorbic acid, docosahexaenoic acid, or eicosapentaenoic acid.
  • composition containing the combination according to the invention makes it possible to obtain a clear whitening of the skin.
  • the invention also relates to a depigmenting composition for the skin comprising, in a physiologically acceptable medium, mequinol, at least one unsaturated or polyunsaturated fatty acid and at least one sunscreen.
  • the composition according to the invention advantageously comprises between 0.0001 and 20% by weight of mequinol relative to the total weight of the composition and between 0.0001 and 20% by weight of fatty acid relative to the total weight of the composition, and preferably, respectively, between 0.001 and 10% by weight of mequinol relative to the total weight of the composition and between 0.025 and 10% by weight of fatty acid relative to the total weight of the composition.
  • the composition can also comprise at least one sunscreen in preferential concentrations ranging from 0.001 to 30.00% by weight relative to the total weight of the composition.
  • sun filters non-limiting examples that may be mentioned include physical sun filters such as titanium dioxide, zinc oxide and chemical sun filters such as Poctocrylene, ethylhexyl methoxycinnamate, octyl salicylate , avobenzone, oxybenzone, ecamsule or drometrizole trisiloxane or their mixtures.
  • Each sunscreen can be added at a concentration ranging from 0.001 to 20% by weight relative to the total weight of the composition.
  • the composition may include several sun filters.
  • each sunscreen can be added at a concentration ranging from 0.001 to 20% by weight relative to the total weight of the composition.
  • compositions according to the invention can also comprise any additive usually used in the cosmetic or pharmaceutical field, such as sequestrants, antioxidants, preservatives, fillers, electrolytes, humectants, dyes, bases or acids usual, mineral or organic, perfumes, essential oils, cosmetic active ingredients, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds, soothing and protective agents for the skin.
  • any additive usually used in the cosmetic or pharmaceutical field such as sequestrants, antioxidants, preservatives, fillers, electrolytes, humectants, dyes, bases or acids usual, mineral or organic, perfumes, essential oils, cosmetic active ingredients, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds, soothing and protective agents for the skin.
  • any additive usually used in the cosmetic or pharmaceutical field such as sequestrants, antioxidants, preservatives, fillers, electrolytes, humectants, dyes, bases or acids usual, mineral or organic, perfume
  • additives can be present in the composition in an amount of 0.001 to 20% by weight relative to the total weight of the composition.
  • the present invention also relates to a pharmaceutical composition as described above as a medicament.
  • the present invention also relates to a cosmetic composition.
  • compositions containing the combination according to the invention can have all the galenical forms normally used for a topical application, for example under form of solutions, gels, dispersions of the lotion or serum type, of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or vice versa (E / H), or suspensions or emulsions of soft, semi-solid or solid consistency of the cream or gel type, or alternatively of microemulsions, microcapsules, microparticles or vesicular dispersions of the ionic and / or nonionic type.
  • These compositions are prepared according to the usual methods.
  • the cosmetic or dermatological compositions of the invention may contain adjuvants customary in the cosmetic or dermatological field, such as emulsifiers, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents other than titanium oxide and ⁇ -hydroxy acid, preservatives, antioxidants, perfumes, fillers, filters and coloring matters.
  • adjuvants customary in the cosmetic or dermatological field, such as emulsifiers, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents other than titanium oxide and ⁇ -hydroxy acid, preservatives, antioxidants, perfumes, fillers, filters and coloring matters.
  • the amounts of these various adjuvants are those conventionally used in the cosmetic and / or dermatological fields, and for example from 0.01% to 20% of the total weight of the composition.
  • These adjuvants depending on their nature, can be introduced into the fatty phase, into the aqueous phase and / or into the lipid vesicles.
  • the invention also relates to the use of the composition according to the invention as described above in the pharmaceutical and cosmetic field.
  • compositions of the invention are particularly suitable for the treatment and prevention of pigmentation disorders.
  • the compositions of the invention are suitable for the treatment and prevention of hyperpigmentary disorders such as melasma, chloasma, lentigines, senile lentigo, vitiligo, freckles, post-inflammatory hyperpigmentations due to abrasion. , a burn, a scar, a dermatosis, a contact allergy; nevi, hyperpigmentations with genetic determinism, hyperpigmentations of metabolic or drug origin, melanomas or any other pigmentary lesions, in particular those induced by photo-induced or chronological aging of the skin and integuments.
  • compositions according to the invention are suitable for the treatment of melasma.
  • the compositions according to the invention also find an application in the cosmetic field, in particular in the protection against the harmful aspects of the sun, in particular, against pigmentary spots.
  • the invention also relates to a non-therapeutic cosmetic treatment process for beautifying the skin and / or improving its surface appearance, characterized in that a composition is applied to the skin and / or its integuments comprising mequinol and an unsaturated or polyunsaturated fatty acid.

Abstract

The invention relates to a depigmenting composition of the skin, comprising mequinol and at least one unsaturated fatty acid in a physiologically acceptable medium. The invention also relates to the pharmaceutical or cosmetic use thereof.

Description

COMPOSITION DERMATOLOGIQUE POUR LE TRAITEMENT DES DESORDRES PIGMENTAIRES DE LA PEAU DERMATOLOGICAL COMPOSITION FOR THE TREATMENT OF PIGMENTARY DISORDERS OF THE SKIN
L'invention se rapporte à une composition dépigmentante de la peau comprenant, dans un milieu physiologiquement acceptable, du mequinol (ou 4-hydroxyanisole), et au moins un acide gras insaturé ou poly-insaturé et son utilisation pharmaceutique ou cosmétique. La composition selon l'invention peut également contenir un filtre solaire.The invention relates to a skin depigmenting composition comprising, in a physiologically acceptable medium, mequinol (or 4-hydroxyanisole), and at least one unsaturated or polyunsaturated fatty acid and its pharmaceutical or cosmetic use. The composition according to the invention may also contain a sunscreen.
La pigmentation de la peau résulte de la synthèse de la mélanine dans les mélanocytes du derme par la transformation de la tyrosine sous l'influence d'une enzyme cupro- protéique la tyrosinase.The pigmentation of the skin results from the synthesis of melanin in the melanocytes of the dermis by the transformation of tyrosine under the influence of a cuproprotein enzyme tyrosinase.
On peut donc obtenir un effet de dépigmentation de la peau en utilisant un composé qui dégrade la mélanine ou un inhibiteur de la tyrosinase qui bloque le mécanisme de transformation de la tyrosine en mélanine.We can therefore obtain a depigmentation effect on the skin by using a compound which degrades melanin or a tyrosinase inhibitor which blocks the mechanism of transformation of tyrosine into melanin.
Le mequinol est un composé dont l'activité dépigmentante est connue. En effet celui-ci agit comme substrat de la tyrosinase et bloque donc le mécanisme de synthèse de la mélanine au niveau du derme (Riley P, Journal of Pathology (1969), 97(2), 185-191) En effet, les désordres pigmentaires tels que l'hyperpigmentation sont le résultat d'une production excessive de mélanine. En bloquant ou diminuant cette synthèse, on peut obtenir un effet de dépigmentationMequinol is a compound whose depigmenting activity is known. Indeed it acts as a substrate for tyrosinase and therefore blocks the mechanism of melanin synthesis in the dermis (Riley P, Journal of Pathology (1969), 97 (2), 185-191) Indeed, disorders Pigments such as hyperpigmentation are the result of excessive production of melanin. By blocking or decreasing this synthesis, one can obtain a depigmentation effect
La Demanderesse a découvert de manière surprenante que la combinaison du mequinol et d'un acide gras permettait d'obtenir par effet de synergie une réponse dépigmentante beaucoup plus efficace que celle obtenue avec le mequinol seul et surtout de procurer un meilleur confort d'utilisation.The Applicant has surprisingly discovered that the combination of mequinol and a fatty acid makes it possible to obtain, by synergistic effect, a depigmenting response much more effective than that obtained with mequinol alone and above all to provide better comfort of use.
Ando et al. dans « Linoleic acid an alpha-linolenic acid lighten UV-induced hyperpigmentation on the skin » arch. Dermatol. Res. Vol. 290, 1998, décrivent la capacité de deux acides gras de prévenir l'hyperpigmentation provoquée par l'exposition au soleil.Ando et al. in “Linoleic acid an alpha-linolenic acid lighten UV-induced hyperpigmentation on the skin” arch. Dermatol. Res. Flight. 290, 1998, describe the ability of two fatty acids to prevent hyperpigmentation caused by exposure to the sun.
Il reste néanmoins nécessaire de trouver des compositions ayant une activité dépigmentante accrue. L'invention se rapporte à une composition dépigmentante de la peau comprenant dans un milieu physiologiquement acceptable, du mequinol et un acide gras insaturé.However, it remains necessary to find compositions having increased depigmenting activity. The invention relates to a depigmenting composition for the skin comprising, in a physiologically acceptable medium, mequinol and an unsaturated fatty acid.
On entend par milieu physiologiquement acceptable, un milieu compatible avec la peau, les muqueuses et/ou les phanères.The term “physiologically acceptable medium” means a medium compatible with the skin, the mucous membranes and / or the integuments.
On entend par acide gras un constituant des lipides. Les acides gras diffèrent les uns des autres par leur longueur de chaîne et leur degré de saturation à savoir le nombre de carbone constituant la chaîne et la nature des liaisons, simple, ou doubles reliant les atomes de carbone entre eux.By fatty acid is meant a constituent of lipids. The fatty acids differ from each other by their chain length and their degree of saturation, namely the number of carbon constituting the chain and the nature of the bonds, single or double, connecting the carbon atoms to each other.
On différencie donc les acides gras saturés, dont les atomes de carbone sont reliés entre eux par des liaisons simples, et les acides gras insaturés, dont certains atomes de carbones sont reliés entre eux par une ou plusieurs liaisons doubles.A distinction is therefore made between saturated fatty acids, whose carbon atoms are linked together by single bonds, and unsaturated fatty acids, whose certain carbon atoms are linked together by one or more double bonds.
Par acide gras insaturé selon l'invention, on entend, les acides gras insaturés et les acides gras poly-insaturé.The term “unsaturated fatty acid according to the invention” means the unsaturated fatty acids and the polyunsaturated fatty acids.
A titre d'exemple non limitatif d'acide gras insaturé selon l'invention, on peut citer l'acide linoléique, l'acide arachidonique, l'acide sorbique, l'acide docosahexaénoique, ou l'acide eicosapentaénoique.By way of nonlimiting example of unsaturated fatty acid according to the invention, mention may be made of linoleic acid, arachidonic acid, sorbic acid, docosahexaenoic acid, or eicosapentaenoic acid.
L'application d'une composition contenant l'association selon l'invention permet d'obtenir un net blanchiment de la peau.The application of a composition containing the combination according to the invention makes it possible to obtain a clear whitening of the skin.
L'invention se rapporte aussi à une composition dépigmentante de la peau comprenant dans un milieu physiologiquement acceptable, du mequinol, au moins un acide gras insaturé ou poly-insaturé et au moins un filtre solaire.The invention also relates to a depigmenting composition for the skin comprising, in a physiologically acceptable medium, mequinol, at least one unsaturated or polyunsaturated fatty acid and at least one sunscreen.
La composition selon l'invention comprend avantageusement entre 0,0001 et 20 % en poids de mequinol par rapport au poids total de la composition et entre 0,0001 et 20 % en poids d'acide gras par rapport au poids total de la composition, et de préférence, respectivement, entre 0,001 et 10 % en poids de mequinol par rapport au poids total de la composition et entre 0,025 et 10 % en poids d'acide gras par rapport au poids total de la composition. La composition peut également comprendre au moins un filtre solaire dans des concentrations préférentielles allant de 0.001 à 30.00 % en poids par rapport au poids total de la composition.The composition according to the invention advantageously comprises between 0.0001 and 20% by weight of mequinol relative to the total weight of the composition and between 0.0001 and 20% by weight of fatty acid relative to the total weight of the composition, and preferably, respectively, between 0.001 and 10% by weight of mequinol relative to the total weight of the composition and between 0.025 and 10% by weight of fatty acid relative to the total weight of the composition. The composition can also comprise at least one sunscreen in preferential concentrations ranging from 0.001 to 30.00% by weight relative to the total weight of the composition.
Parmi les filtres solaires, on peut citer à titre d'exemple non limitatif, les filtre solaires physiques tels que le dioxyde de titane, l'oxyde de zinc et les filtres solaires chimiques tels que Poctocrylene, l'ethylhexyl methoxycinnamate, l'octyl salicylate, l'avobenzone, l'oxybenzone, l'ecamsule ou le drometrizole trisiloxane ou leurs mélanges. Chaque filtre solaire pourra être ajouté à une concentration allant de 0.001 à 20% en poids par rapport au poids total de la composition.Among the sun filters, non-limiting examples that may be mentioned include physical sun filters such as titanium dioxide, zinc oxide and chemical sun filters such as Poctocrylene, ethylhexyl methoxycinnamate, octyl salicylate , avobenzone, oxybenzone, ecamsule or drometrizole trisiloxane or their mixtures. Each sunscreen can be added at a concentration ranging from 0.001 to 20% by weight relative to the total weight of the composition.
Dans une variante de réalisation de la présente invention, la composition pourra comprendre plusieurs filtres solaires. Auquel cas, chaque filtre solaire pourra être ajouté à une concentration allant de 0.001 à 20% en poids par rapport au poids total de la composition.In an alternative embodiment of the present invention, the composition may include several sun filters. In which case, each sunscreen can be added at a concentration ranging from 0.001 to 20% by weight relative to the total weight of the composition.
Les compositions selon l'invention peuvent comprendre en outre tout additif usuellement utilisé dans le domaine cosmétique ou pharmaceutique, tel que des séquestrants, des antioxydants, des conservateurs, des charges, des électrolytes, des humectants, des colorants, de bases ou d'acides usuels, minéraux ou organiques, des parfums, des huiles essentielles, des actifs cosmétiques, des hydratants, des vitamines, des acides gras essentiels, des sphingolipides, des composés auto-bronzants, des agents apaisants et protecteurs de la peau. Bien entendu l'homme du métier veillera à choisir ce ou ces éventuels composés complémentaires, et/ou leur quantité, de manière telle que les propriétés avantageuses de la composition selon l'invention ne soient pas, ou substantiellement pas, altérées.The compositions according to the invention can also comprise any additive usually used in the cosmetic or pharmaceutical field, such as sequestrants, antioxidants, preservatives, fillers, electrolytes, humectants, dyes, bases or acids usual, mineral or organic, perfumes, essential oils, cosmetic active ingredients, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds, soothing and protective agents for the skin. Of course, a person skilled in the art will take care to choose this or these optional additional compounds, and / or their quantity, in such a way that the advantageous properties of the composition according to the invention are not, or not substantially, altered.
Ces additifs peuvent être présents dans la composition à raison de 0,001 à 20 % en poids par rapport au poids total de la composition.These additives can be present in the composition in an amount of 0.001 to 20% by weight relative to the total weight of the composition.
La présente invention a aussi pour objet une composition pharmaceutique telle que décrite précédemment à titre de médicament.The present invention also relates to a pharmaceutical composition as described above as a medicament.
La présente invention a également pour objet une composition cosmétique.The present invention also relates to a cosmetic composition.
Les compositions contenant l'association selon l'invention peuvent présenter toutes les formes galéniques normalement utilisées pour une application topique, par exemple sous forme de solutions, de gels, de dispersions du type lotion ou sérum, d'émulsions de consistance liquide ou semi-liquide du type lait, obtenues par dispersion d'une phase grasse dans une phase aqueuse (H/E) ou inversement (E/H), ou de suspensions ou émulsions de consistance molle, semi-solide ou solide du type crème ou gel, ou encore de microémulsions, de microcapsules, de microparticules ou de dispersions vésiculaires de type ionique et/ou non ionique. Ces compositions sont préparées selon les méthodes usuelles.The compositions containing the combination according to the invention can have all the galenical forms normally used for a topical application, for example under form of solutions, gels, dispersions of the lotion or serum type, of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or vice versa (E / H), or suspensions or emulsions of soft, semi-solid or solid consistency of the cream or gel type, or alternatively of microemulsions, microcapsules, microparticles or vesicular dispersions of the ionic and / or nonionic type. These compositions are prepared according to the usual methods.
De façon connue, les compositions cosmétiques ou dermatologiques de l'invention peuvent contenir des adjuvants habituels dans le domaine cosmétique ou dermatologique, tels que les émulsionnants, les gélifiants hydrophiles ou lipophiles, les actifs hydrophiles ou lipophiles différents de l'oxyde de titane et de l'α-hydroxyacide, les conservateurs, les antioxydants, les parfums, les charges, les filtres et les matières colorantes. Les quantités de ces différents adjuvants sont celles classiquement utilisées dans les domaines cosmétique et/ou dermatologique, et par exemple de 0,01 % à 20 % du poids total de la composition. Ces adjuvants, selon leur nature, peuvent être introduits dans la phase grasse, dans la phase aqueuse et/ou dans les vésicules lipidiques.In a known manner, the cosmetic or dermatological compositions of the invention may contain adjuvants customary in the cosmetic or dermatological field, such as emulsifiers, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents other than titanium oxide and α-hydroxy acid, preservatives, antioxidants, perfumes, fillers, filters and coloring matters. The amounts of these various adjuvants are those conventionally used in the cosmetic and / or dermatological fields, and for example from 0.01% to 20% of the total weight of the composition. These adjuvants, depending on their nature, can be introduced into the fatty phase, into the aqueous phase and / or into the lipid vesicles.
L'invention se rapporte également à l'utilisation de la composition selon l'invention telle que décrite précédemment dans le domaine pharmaceutique et cosmétique.The invention also relates to the use of the composition according to the invention as described above in the pharmaceutical and cosmetic field.
Les compositions de l'invention conviennent particulièrement bien au traitement et à la prévention des désordres de la pigmentation. Préférentiellement, les compositions de l'invention conviennent au traitement et à la prévention des désordres hyperpigmentaires tels que le melasma, le chloasma, les lentigines, le lentigo sénile, le vitiligo, les taches de rousseur, les hyperpigmentations post-inflammatoires dues à une abrasion, une brûlure, une cicatrice, une dermatose, une allergie de contact; les nevi, les hyperpigmentations à déterminisme génétique, les hyperpigmentations d'origine métabolique ou médicamenteuse, les mélanomes ou toutes autres lésions pigmentaires, notamment celles induites par le vieillissement photo induit ou chronologique de la peau et des phanères.The compositions of the invention are particularly suitable for the treatment and prevention of pigmentation disorders. Preferably, the compositions of the invention are suitable for the treatment and prevention of hyperpigmentary disorders such as melasma, chloasma, lentigines, senile lentigo, vitiligo, freckles, post-inflammatory hyperpigmentations due to abrasion. , a burn, a scar, a dermatosis, a contact allergy; nevi, hyperpigmentations with genetic determinism, hyperpigmentations of metabolic or drug origin, melanomas or any other pigmentary lesions, in particular those induced by photo-induced or chronological aging of the skin and integuments.
Plus préférentiellement les compositions selon l'invention conviennent au traitement du melasma. Les compositions selon l'invention trouvent également une application dans le domaine cosmétique, en particulier dans la protection contre les aspects néfastes du soleil, en particulier, contre les taches pigmentaires.More preferably, the compositions according to the invention are suitable for the treatment of melasma. The compositions according to the invention also find an application in the cosmetic field, in particular in the protection against the harmful aspects of the sun, in particular, against pigmentary spots.
L'invention porte également sur un procédé de traitement cosmétique non thérapeutique d'embellissement de la peau et/ou d'amélioration de son aspect de surface, caractérisé par le fait que l'on applique sur la peau et/ou ses phanères une composition comprenant du mequinol et un acide gras insaturé ou poly-insaturé.The invention also relates to a non-therapeutic cosmetic treatment process for beautifying the skin and / or improving its surface appearance, characterized in that a composition is applied to the skin and / or its integuments comprising mequinol and an unsaturated or polyunsaturated fatty acid.
Les exemples de formulations ci-dessous permettent d'illustrer les compositions selon l'invention, sans toutefois en limiter la portée. Des exemples illustrant l'activité dépigmentante des différentes compositions selon l'invention, sont également décrits.The examples of formulations below make it possible to illustrate the compositions according to the invention, without however limiting their scope. Examples illustrating the depigmenting activity of the various compositions according to the invention are also described.
Dans les compositions ci-après (exemples 1 à 6), les proportions des différents constituants sont exprimées en pourcentage en poids par rapport au poids total de la composition.In the compositions below (examples 1 to 6), the proportions of the various constituents are expressed as a percentage by weight relative to the total weight of the composition.
Exemple 1Example 1
Figure imgf000006_0001
Exemple 2 :
Figure imgf000006_0001
Example 2:
Figure imgf000007_0001
Figure imgf000007_0001
Exemple 3 :Example 3:
Figure imgf000007_0002
Figure imgf000007_0002
Exemple 4 Example 4
Figure imgf000008_0001
Figure imgf000008_0001
Exemple 5 :Example 5:
Figure imgf000008_0002
Figure imgf000008_0002
Exemple 6
Figure imgf000009_0001
Example 6
Figure imgf000009_0001

Claims

Revendications claims
1. Composition dépigmentante de la peau, comprenant du mequinol et un acide gras insaturé, dans un véhicule physiologiquement acceptable.1. Skin depigmenting composition, comprising mequinol and an unsaturated fatty acid, in a physiologically acceptable vehicle.
2. Composition selon la revendication 1 , caractérisée en ce que l'acide gras insaturé est l'acide linoléique, l'acide arachidonique, l'acide sorbique, l'acide docosahexaénoique, ou l'acide eicosapentaénoique.2. Composition according to claim 1, characterized in that the unsaturated fatty acid is linoleic acid, arachidonic acid, sorbic acid, docosahexaenoic acid, or eicosapentaenoic acid.
3. Composition selon l'une quelconque des revendications de 1 à 2, caractérisée en ce qu'elle contient également au moins un filtre solaire.3. Composition according to any one of claims 1 to 2, characterized in that it also contains at least one sunscreen.
4. Composition selon l'une quelconque des revendications de 1 à 3 à titre de médicament.4. Composition according to any one of claims 1 to 3 as a medicament.
5. Composition selon d'une quelconque des revendications 1 à 3 caractérisé en ce que la composition est une composition cosmétique.5. Composition according to any one of claims 1 to 3 characterized in that the composition is a cosmetic composition.
6. Utilisation d'une composition dépigmentante de la peau, comprenant du mequinol et au un acide gras insaturé dans un véhicule physiologiquement acceptable pour la fabrication d'une préparation pharmaceutique destinée à prévenir ou à traiter des désordres de la pigmentation.6. Use of a depigmenting composition for the skin, comprising mequinol and an unsaturated fatty acid in a physiologically acceptable vehicle for the manufacture of a pharmaceutical preparation intended for preventing or treating disorders of pigmentation.
7. Utilisation selon la revendication 6 pour la fabrication d'une préparation pharmaceutique destinée à prévenir ou à traiter le melasma.7. Use according to claim 6 for the manufacture of a pharmaceutical preparation intended to prevent or treat melasma.
8. Utilisation cosmétique d'une composition dépigmentante de la peau, comprenant de du mequinol et un acide gras insaturé dans un véhicule physiologiquement acceptable, pour la protection contre les aspects néfastes du soleil.8. Cosmetic use of a depigmenting composition for the skin, comprising of mequinol and an unsaturated fatty acid in a physiologically acceptable vehicle, for protection against the harmful aspects of the sun.
9. Utilisation cosmétique d'une composition dépigmentante de la peau, comprenant de du mequinol et un acide gras insaturé dans un véhicule physiologiquement acceptable comme agent de blanchiment de la peau.9. Cosmetic use of a depigmenting composition for the skin, comprising mequinol and an unsaturated fatty acid in a physiologically acceptable vehicle as a skin whitening agent.
10. Procédé de traitement cosmétique non thérapeutique d'embellissement de la peau et/ou d'amélioration de son aspect de surface, caractérisé par le fait que l'on applique sur la peau et/ou ses phanères une composition comprenant du mequinol et un acide gras insaturé. 10. A non-therapeutic cosmetic treatment process for beautifying the skin and / or improving its surface appearance, characterized in that one applies on the skin and / or its integuments a composition comprising mequinol and an unsaturated fatty acid.
PCT/FR2005/001213 2004-05-14 2005-05-13 Dermatological composition for the treatment of pigmentary disorders of the skin WO2005115324A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2007512293A JP2007537218A (en) 2004-05-14 2005-05-13 Dermatological composition for treating skin pigmentation
EP05770836A EP1746971A1 (en) 2004-05-14 2005-05-13 Dermatological composition for the treatment of pigmentary disorders of the skin
CA002564100A CA2564100A1 (en) 2004-05-14 2005-05-13 Dermatological composition for the treatment of pigmentary disorders of the skin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0405283 2004-05-14
FR0405283A FR2870124B1 (en) 2004-05-14 2004-05-14 DERMATOLOGICAL COMPOSITION FOR THE TREATMENT OF PIGMENT DISORDERS OF THE SKIN

Publications (1)

Publication Number Publication Date
WO2005115324A1 true WO2005115324A1 (en) 2005-12-08

Family

ID=34945901

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/001213 WO2005115324A1 (en) 2004-05-14 2005-05-13 Dermatological composition for the treatment of pigmentary disorders of the skin

Country Status (5)

Country Link
EP (1) EP1746971A1 (en)
JP (1) JP2007537218A (en)
CA (1) CA2564100A1 (en)
FR (1) FR2870124B1 (en)
WO (1) WO2005115324A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047633A1 (en) * 2006-10-10 2008-04-24 Maruha Corporation Aliphatic compound-containing skin whitening agent

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2984730A1 (en) * 2011-12-22 2013-06-28 Diverchim NEW ANTI-AGE AND DEPIGMENTING COSMETIC COMPOSITIONS

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01186810A (en) * 1988-01-20 1989-07-26 Sunstar Inc Skin beautifying cosmetic
JPH01186811A (en) * 1988-01-20 1989-07-26 Sunstar Inc Skin beautifying cosmetic
EP0381057A2 (en) * 1989-01-28 1990-08-08 Sansho Seiyaku Co., Ltd. Chemical composition for external application
WO2000076494A1 (en) * 1997-08-05 2000-12-21 Gordon Benjamin D Compositions and systems for the treatment of hyperpigmentation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3176572B2 (en) * 1997-09-02 2001-06-18 エフ・ディ−・ケイ株式会社 Alkaline battery
JP3826227B2 (en) * 1997-09-12 2006-09-27 宮田工業株式会社 battery pack

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01186810A (en) * 1988-01-20 1989-07-26 Sunstar Inc Skin beautifying cosmetic
JPH01186811A (en) * 1988-01-20 1989-07-26 Sunstar Inc Skin beautifying cosmetic
EP0381057A2 (en) * 1989-01-28 1990-08-08 Sansho Seiyaku Co., Ltd. Chemical composition for external application
WO2000076494A1 (en) * 1997-08-05 2000-12-21 Gordon Benjamin D Compositions and systems for the treatment of hyperpigmentation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRIGANTI S ET AL: "Chemical and Instrumental Approaches to Treat Hyperpigmentation (Review: Innovative Technology)", PIGMENT CELL RESEARCH, MUNKSGAARD INTERNATIONAL PUBLISHERS, CAMBRIDGE, MA, DK, vol. 16, 2003, pages 101 - 110, XP002262229, ISSN: 0893-5785 *
H. ANDO: "Linoleic acid and alpha-linolenic acid lighten ultraviolet-induced hyperpigmentation on the skin", ARCH. DERMATOL. RES., vol. 290, 1998, pages 375 - 381, XP002310144 *
PATENT ABSTRACTS OF JAPAN vol. 0134, no. 72 (C - 647) 25 October 1989 (1989-10-25) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047633A1 (en) * 2006-10-10 2008-04-24 Maruha Corporation Aliphatic compound-containing skin whitening agent
JP4954988B2 (en) * 2006-10-10 2012-06-20 株式会社マルハニチロ水産 Whitening agent containing aliphatic compounds

Also Published As

Publication number Publication date
FR2870124A1 (en) 2005-11-18
FR2870124B1 (en) 2006-07-07
JP2007537218A (en) 2007-12-20
EP1746971A1 (en) 2007-01-31
CA2564100A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
EP0661038A1 (en) Depigmentation composition for the simultaneous treatment of the superficial skinlayers and the deep skinlayers
EP1252882B1 (en) Process to increase the threshold tolerance of the sensitive skin
EP1064931A1 (en) Cosmetic composition containing at least an hydroxystilbene and ascorbic acid
CA2685482A1 (en) Dermatological and cosmetic depigmenting compositions, methods for the preparation thereof and uses thereof
EP0747043A1 (en) Use of salicylic acid derivatives for skin whitening
FR2798590A1 (en) USE OF ALVERINE TO REDUCE WRINKLES
CA2568262A1 (en) Hydroalcoholic depigmentation gel comprising mequinol and adapalene
FR2849597A1 (en) Cosmetic composition for treating greasy skin, contains a dicarboxylic fatty acid or derivative, reduces secretion of sebum and inhibits lipogenesis
WO2005102337A2 (en) Use of a sphingoid base associated with nicotinic acid or a nicotinic acid amide in the form of a depigmentation agent
EP0771557A1 (en) Use of ascorbic acid as the actif for the treatment of seborrhea in a cosmetic and/or dermatalogical composition
WO2005115365A2 (en) Pharmaceutical or cosmetic composition comprising mequinol and at least one depigmenting agent
EP1746971A1 (en) Dermatological composition for the treatment of pigmentary disorders of the skin
EP1019017B1 (en) Association of phenol derivatives with extract of iridaceae family for lightening the skin and superficial body growth and composition containing same
WO2002085362A2 (en) Dermatological composition comprising nicotinic acid or an amide, and a sphingoid base
WO2007066041A2 (en) Skin depigmentation composition containing a naphthonic acid derivative
FR2946249A1 (en) DEPIGMENTING TOPICAL COMPOSITIONS AND USES THEREOF.
EP1566168A1 (en) Dermo-cosmetic compositions for depigmenting and use of it
EP1755542A1 (en) Mequinol-based dermatological depigmenting composition
EP0940140A1 (en) Topical composition of alpha hydroxy acids and ceramides for the treatment of skin conditions
FR3132638A1 (en) Use of rhamnolipid(s) to prevent staining of cutaneous blackheads
FR2788693A1 (en) Use of unfermented honey as an agent for depigmenting and/or lightening the skin, body hair or head hair and/or for treating liver spots
CA2511901A1 (en) Cosmetic composition for greasy skin care, containing a carboxylic fatty acid or a derivative thereof
EP1252883A1 (en) Process for reducing partially or completely the symptoms associated with the histamin release within the human body
WO2021009142A1 (en) Composition comprising at least one oxazoline for inhibiting the growth of malassezia yeasts involved in cradle cap, in particular
WO2002005779A1 (en) Composition, in particular cosmetic, containing dhea and/or its precursors or derivatives, and a vitamin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005770836

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2564100

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007512293

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005770836

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005770836

Country of ref document: EP